Antibody Partnering Terms and Agreement Report 2014 – The Latest and Most Comprehensive Market Research Offering

Share Article announces new research report on Antibody Partnering Terms and Agreements to it's huge collection. Visit:

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details to sales(at)researchmoz(dot)us.

The report collates disparate data and analyzes the various aspects of the process of forming an antibody partnership as well as the major reasons for sharing the platform for antibody research and commercialization, offering detailed explanations of both.

To get a sample report with TOC, click here:

It also contains links to 900 contracts regarding antibody partnering drawn up between various biopharma and biotech companies, for easier comprehension of the process and value each party derives from the agreement. The reports offer an easily comprehensible yet insightful look into the dynamics of antibody partnership agreements. This also provides invaluable insight into the structuring of payment clauses and triggers, which are a vital part of antibody partnering agreements.

The report covers deals in different types of antibody-related biopharma sectors such as monoclonal antibodies, antibody-drug conjugates, chimeric mAb, murine mAb humanized mAb, human aAb, polyclonal antibodies, etc.

The history of antibody partnering and notable agreements over the years is elaborated upon in the report to provide a background of the field. Top deals in antibody partnering are listed; antibody partnering in big biotech and biopharma companies is given special attention. The companies who have signed antibody partnering agreements are profiled for a better comprehension of the market condition in biotech and biopharma industries. The deals in biotech and biopharma are accompanied with tips for making the best use of antibody partnering deals; this explains the benefit for both parties.

Antibody partnering deals are categorized by the type of deal made, the type of disease in which the antibody in question is of use, and the stage of development at which the deal is made. The report analyzes each of the three categories to work out the method and reasoning. The process is explained by giving the examples of two antibody partnership agreements signed in 2012: between ADMA Biologistics and Biotest and between Amgen and AstraZeneca.

Browse a Full Report with TOC:

The report contains a directory of actual antibody partnering agreements. This is sorted by the type of deal, the nature of the disease in question, and the stage of development at the time of the agreement.

Figures are used to express various data elaborated upon in the report, for easier comprehension. These include annual statistics of various kinds totaled from 2009 to 2014. The data for antibody partnering deals of each type from 2009 to 2014, as well as various other statistics, are expressed in a total of 67 figures.

The report also contains detailed information about facilities for online antibody partnering, upcoming antibody partnering events, and more resources that explain the field of antibody partnering.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Thoras
Email >
Follow us on
Visit website